PubRank

Amit Bar-Or

Author PubWeight™ 141.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 12.90
2 Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012 7.58
3 Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011 3.76
4 Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007 2.68
5 Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007 2.64
6 Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol 2010 2.63
7 Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006 2.62
8 The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010 2.45
9 B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012 2.36
10 MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 2011 2.12
11 Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006 2.06
12 Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011 1.92
13 Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004 1.89
14 Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007 1.88
15 Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 2014 1.75
16 Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007 1.73
17 Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 2012 1.73
18 Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003 1.59
19 NeuriteTracer: a novel ImageJ plugin for automated quantification of neurite outgrowth. J Neurosci Methods 2007 1.59
20 Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008 1.58
21 Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012 1.55
22 Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol 2010 1.51
23 Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009 1.50
24 TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol 2011 1.47
25 B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 2011 1.45
26 Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology 2013 1.44
27 Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 2005 1.43
28 Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006 1.36
29 Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004 1.34
30 Quantitative analysis of human endogenous retrovirus-W env in neuroinflammatory diseases. AIDS Res Hum Retroviruses 2006 1.34
31 Microglia and multiple sclerosis. J Neurosci Res 2005 1.34
32 Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann Neurol 2012 1.32
33 Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 2013 1.27
34 Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013 1.27
35 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol 2012 1.21
36 miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol 2013 1.21
37 Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005 1.20
38 Determinants of human B cell migration across brain endothelial cells. J Immunol 2003 1.19
39 Lesion distribution in children with clinically isolated syndromes. Ann Neurol 2008 1.17
40 Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 2003 1.16
41 B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nat Rev Immunol 2008 1.14
42 Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol 2009 1.10
43 Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 2011 1.10
44 Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med 2003 1.10
45 Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol 2005 1.09
46 Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann Neurol 2010 1.08
47 Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol 2006 1.06
48 Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol 2008 1.05
49 Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia 2007 1.03
50 Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci 2008 1.03
51 Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab 2011 1.02
52 Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004 1.02
53 Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 2011 1.02
54 Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 2003 1.01
55 From bench to MS bedside: challenges translating biomarker discovery to clinical practice. J Neuroimmunol 2012 0.99
56 Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 2005 0.98
57 The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. Med Decis Making 2002 0.98
58 Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol 2014 0.97
59 Differential responses of human microglia and blood-derived myeloid cells to FTY720. J Neuroimmunol 2010 0.97
60 Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler 2013 0.96
61 Myelin regulates immune cell adhesion and motility. Exp Neurol 2009 0.96
62 Regulation of miRNA 219 and miRNA Clusters 338 and 17-92 in Oligodendrocytes. Front Genet 2012 0.94
63 Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J Immunol 2011 0.94
64 Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol 2011 0.93
65 Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin Immunol 2010 0.92
66 MicroRNA dysregulation in multiple sclerosis. Front Genet 2013 0.92
67 Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 2012 0.91
68 Dendritic cell differentiation signals induce anti-inflammatory properties in human adult microglia. J Immunol 2008 0.90
69 International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology 2013 0.89
70 Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother 2011 0.87
71 Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS). J Neuroimmunol 2011 0.87
72 A condensed performance-validation strategy for multiplex detection kits used in studies of human clinical samples. J Immunol Methods 2012 0.86
73 Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol 2015 0.86
74 Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology 2013 0.85
75 Fatigue in post-poliomyelitis syndrome: association with disease-related, behavioral, and psychosocial factors. PM R 2009 0.85
76 Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation. J Neuroinflammation 2013 0.85
77 Polysomnographic measures of disturbed sleep are associated with reduced quality of life in multiple sclerosis. J Neurol Sci 2012 0.84
78 Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol 2014 0.84
79 A proteome map of axoglial specializations isolated and purified from human central nervous system. Glia 2010 0.84
80 Pharmacological treatment of early multiple sclerosis. Drugs 2008 0.84
81 CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. J Autoimmun 2003 0.83
82 What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004 0.83
83 Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS. Neurology 2014 0.82
84 Masquerades of acquired demyelination in children: experiences of a national demyelinating disease program. J Child Neurol 2012 0.82
85 Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. Glia 2003 0.81
86 EBV and brain matter(s)? Neurology 2010 0.81
87 Neurite outgrowth is differentially impacted by distinct immune cell subsets. Mol Cell Neurosci 2011 0.80
88 Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult Scler 2013 0.80
89 Emerging multiple sclerosis disease-modifying therapies. Curr Opin Neurol 2009 0.80
90 Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol 2014 0.80
91 Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Neurology 2013 0.79
92 A further TWEAK to multiple sclerosis pathophysiology. Mol Neurobiol 2013 0.79
93 Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. ISRN Neurol 2013 0.79
94 Innate immune-mediated neuronal injury consequent to loss of astrocytes. J Neuropathol Exp Neurol 2008 0.78
95 Laquinimod in multiple sclerosis. Clin Immunol 2011 0.78
96 Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. Clin Immunol 2004 0.77
97 Beta interferons in clinically isolated syndromes: a meta-analysis. Arq Neuropsiquiatr 2008 0.77
98 Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much? Arch Neurol 2009 0.77
99 Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system. Arch Neurol 2006 0.77
100 Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology 2013 0.77
101 Myeloid lineage cells inhibit neurite outgrowth through a myosin II-dependent mechanism. J Neuroimmunol 2011 0.77
102 MicroRNA Expression Patterns in Human Astrocytes in Relation to Anatomical Location and Age. J Neuropathol Exp Neurol 2016 0.76
103 Antigen-specific therapies in multiple sclerosis. Expert Opin Emerg Drugs 2009 0.76
104 Epidural blood patch in a patient with multiple sclerosis: is it safe? Can J Anaesth 2013 0.75
105 Premature immune senescence in children with MS: Too young to go steady. Neurology 2013 0.75
106 High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc. Acta Neuropathol 2015 0.75
107 Cross-reactivity between epidemiology and immunology in multiple sclerosis. Neurology 2008 0.75
108 8th international congress of neuroimmunology. J Neuroimmunol 2007 0.75
109 B-cell subsets: cellular interactions and relevance in multiple sclerosis. Expert Rev Clin Immunol 2007 0.75
110 Considering a career in neurology research? Heed these words. Ann Neurol 2013 0.75